FDA Approves Johnson & Johnson's Imaavy for Warm Autoimmune Hemolytic Anemia

The U.S. FDA has granted approval to Johnson & Johnson's drug Imaavy for treating warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older who have been previously treated with steroids. This marks Imaavy as the first approved treatment for this rare blood disorder, offering a new therapeutic option for affected individuals.